论文部分内容阅读
目的:探讨肝动脉内化疗栓塞(TACE)对老年人肝癌的疗效,并对TACE术后死亡原因予以分析。材料与方法:回顾性分析83例老年人肝癌行TACE的治疗疗效,治疗一个月内死亡者列为TACE术后早期死亡组,术后一个月以上死亡者列为后期死亡组。比较两组的病死率。结果:总有效率38.5％,1、3、5年生存率分别为50.6％、24％、19.3％。死于TACE并发症者5例,非并发症者60例。结论:TACE是目前治疗中晚期肝癌安全的、有效的微创疗法,伴门脉主干的癌栓并非TACE绝对禁忌症。
Objective: To investigate the efficacy of transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma in the elderly and to analyze the causes of death after TACE. Materials and Methods: The curative effect of TACE in 83 elderly patients with hepatocellular carcinoma was retrospectively analyzed. The patients who died within one month after treatment were listed as the early death after TACE. Those who died more than one month after operation were classified as the late death group. The mortality of the two groups was compared. Results: The total effective rate was 38.5%, and the 1, 3, 5-year survival rates were 50.6%, 24% and 19.3% respectively. 5 died of complications of TACE, 60 cases of noncomplications. Conclusion: TACE is the current minimally invasive and effective minimally invasive therapy for advanced hepatocellular carcinoma. Tumor embolism with portal vein is not an absolute contraindication to TACE.